InDex Pharmaceuticals Holding AB (publ) (INDEX.ST) Research

InDex Pharmaceuticals Holding AB (publ) is a pharmaceutical firm dedicated to developing therapeutic solutions for patients affected by ulcerative colitis. The company's flagship drug candidate, Cobitolimod, is presently in Phase III clinical trials, targeting the treatment of moderate to severe ulcerative colitis. Furthermore, InDex is progressing a pipeline of other DNA-based immunomodulatory sequences, which are in the preclinical phase, designed to address various immunological conditions. This enterprise was established in 2000 and operates from its headquarters in Solna, Sweden.

Market snapshot

Symbol
INDEX.ST
Price
$0.56
Day change
+3.72%
Market cap
$1.9B
P/E ratio
-2.80x
52-week range
0.198-0.926
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Abliva AB (publ) (ABLI.ST)
  • Amniotics AB (publ) (AMNI.ST)
  • CombiGene AB (publ) (COMBI.ST)
  • Cyxone AB (publ) (CYXO.ST)
  • ISR Immune System Regulation Holding AB (publ) (ISR.ST)
  • Kancera AB (publ) (KAN.ST)
  • Medivir AB (publ) (MVIR-B.ST)
  • Probi AB (publ) (PROB.ST)

Open InDex Pharmaceuticals Holding AB (publ) (INDEX.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.